Annual EBITDA
-$7.49 M
+$354.80 K+4.53%
30 June 2024
Summary:
NanoViricides annual earnings before interest, taxes, depreciation & amortization is currently -$7.49 million, with the most recent change of +$354.80 thousand (+4.53%) on 30 June 2024. During the last 3 years, it has risen by +$546.90 thousand (+6.81%). NNVC annual EBITDA is now -487.94% below its all-time high of $1.93 million, reached on 30 June 2015.NNVC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$2.93 M
-$765.80 K-35.37%
01 September 2024
Summary:
NanoViricides quarterly earnings before interest, taxes, depreciation & amortization is currently -$2.93 million, with the most recent change of -$765.80 thousand (-35.37%) on 01 September 2024. Over the past year, it has dropped by -$1.19 million (-68.16%). NNVC quarterly EBITDA is now -171.53% below its all-time high of $4.10 million, reached on 31 March 2014.NNVC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$8.67 M
-$1.19 M-15.87%
01 September 2024
Summary:
NanoViricides TTM earnings before interest, taxes, depreciation & amortization is currently -$8.67 million, with the most recent change of -$1.19 million (-15.87%) on 01 September 2024. Over the past year, it has dropped by -$476.60 thousand (-5.81%). NNVC TTM EBITDA is now -617.14% below its all-time high of $1.68 million, reached on 30 June 2015.NNVC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NNVC EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4.5% | -68.2% | -5.8% |
| 3 y3 years | +6.8% | -20.3% | -3.6% |
| 5 y5 years | +3.1% | -111.4% | -16.5% |
NNVC EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1.4% | +6.8% | -111.4% | +13.3% | -43.3% | +0.3% |
| 5 y | 5 years | -1.4% | +40.8% | -111.4% | +62.7% | -43.3% | +36.8% |
| alltime | all time | -487.9% | +40.8% | -171.5% | +62.7% | -617.1% | +36.8% |
NanoViricides EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.93 M(+35.4%) | -$8.67 M(+15.9%) |
| June 2024 | -$7.49 M(-4.5%) | -$2.17 M(+30.1%) | -$7.49 M(-14.0%) |
| Mar 2024 | - | -$1.66 M(-13.0%) | -$8.70 M(+1.8%) |
| Dec 2023 | - | -$1.91 M(+9.7%) | -$8.55 M(+4.3%) |
| Sept 2023 | - | -$1.74 M(-48.4%) | -$8.20 M(+4.5%) |
| June 2023 | -$7.84 M(+6.3%) | -$3.38 M(+123.2%) | -$7.84 M(+29.5%) |
| Mar 2023 | - | -$1.51 M(-2.8%) | -$6.05 M(-1.5%) |
| Dec 2022 | - | -$1.56 M(+12.4%) | -$6.14 M(-2.9%) |
| Sept 2022 | - | -$1.39 M(-13.0%) | -$6.33 M(-14.2%) |
| June 2022 | -$7.38 M(-8.1%) | -$1.59 M(-0.8%) | -$7.38 M(-3.9%) |
| Mar 2022 | - | -$1.61 M(-7.7%) | -$7.67 M(-4.1%) |
| Dec 2021 | - | -$1.74 M(-28.5%) | -$8.00 M(-4.5%) |
| Sept 2021 | - | -$2.44 M(+29.0%) | -$8.37 M(+4.3%) |
| June 2021 | -$8.03 M(-36.5%) | -$1.89 M(-2.2%) | -$8.03 M(+3.0%) |
| Mar 2021 | - | -$1.93 M(-8.8%) | -$7.79 M(-43.2%) |
| Dec 2020 | - | -$2.12 M(+1.3%) | -$13.73 M(+2.8%) |
| Sept 2020 | - | -$2.09 M(+26.3%) | -$13.36 M(+5.6%) |
| June 2020 | -$12.65 M(+63.7%) | -$1.66 M(-79.0%) | -$12.65 M(-2.9%) |
| Mar 2020 | - | -$7.86 M(+349.7%) | -$13.04 M(+82.6%) |
| Dec 2019 | - | -$1.75 M(+26.1%) | -$7.14 M(-4.1%) |
| Sept 2019 | - | -$1.39 M(-32.0%) | -$7.45 M(-6.0%) |
| June 2019 | -$7.73 M(+5.3%) | -$2.04 M(+3.7%) | -$7.93 M(+7.6%) |
| Mar 2019 | - | -$1.97 M(-4.4%) | -$7.37 M(+0.4%) |
| Dec 2018 | - | -$2.06 M(+10.3%) | -$7.34 M(-5.1%) |
| Sept 2018 | - | -$1.87 M(+26.2%) | -$7.73 M(+5.4%) |
| June 2018 | -$7.34 M(-2.3%) | -$1.48 M(-23.8%) | -$7.34 M(-7.1%) |
| Mar 2018 | - | -$1.94 M(-20.8%) | -$7.90 M(-6.7%) |
| Dec 2017 | - | -$2.45 M(+66.2%) | -$8.47 M(+25.7%) |
| Sept 2017 | - | -$1.47 M(-27.9%) | -$6.74 M(-10.3%) |
| June 2017 | -$7.51 M(-1.1%) | -$2.04 M(-18.6%) | -$7.51 M(+18.8%) |
| Mar 2017 | - | -$2.51 M(+251.7%) | -$6.33 M(-20.7%) |
| Dec 2016 | - | -$713.60 K(-68.3%) | -$7.98 M(-14.0%) |
| Sept 2016 | - | -$2.25 M(+163.0%) | -$9.27 M(+22.2%) |
| June 2016 | -$7.60 M(-493.6%) | -$854.50 K(-79.5%) | -$7.59 M(+8.9%) |
| Mar 2016 | - | -$4.16 M(+107.1%) | -$6.97 M(+784.3%) |
| Dec 2015 | - | -$2.01 M(+256.0%) | -$788.20 K(+1996.3%) |
| Sept 2015 | - | -$564.60 K(+141.6%) | -$37.60 K(-102.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | $1.93 M(-119.8%) | -$233.70 K(-111.6%) | $1.68 M(-138.6%) |
| Mar 2015 | - | $2.02 M(-260.4%) | -$4.35 M(+91.6%) |
| Dec 2014 | - | -$1.26 M(-209.5%) | -$2.27 M(+3.5%) |
| Sept 2014 | - | $1.15 M(-118.4%) | -$2.19 M(-77.2%) |
| June 2014 | -$9.73 M(+28.6%) | -$6.26 M(-252.7%) | -$9.59 M(+86.6%) |
| Mar 2014 | - | $4.10 M(-446.5%) | -$5.14 M(-57.3%) |
| Dec 2013 | - | -$1.18 M(-81.1%) | -$12.04 M(-0.1%) |
| Sept 2013 | - | -$6.25 M(+246.2%) | -$12.05 M(+59.6%) |
| June 2013 | -$7.56 M(+26.3%) | -$1.81 M(-35.7%) | -$7.55 M(+2.9%) |
| Mar 2013 | - | -$2.81 M(+136.0%) | -$7.33 M(+12.7%) |
| Dec 2012 | - | -$1.19 M(-32.0%) | -$6.50 M(-1.4%) |
| Sept 2012 | - | -$1.75 M(+10.1%) | -$6.60 M(+11.2%) |
| June 2012 | -$5.99 M(+0.6%) | -$1.59 M(-19.6%) | -$5.93 M(+12.3%) |
| Mar 2012 | - | -$1.98 M(+54.2%) | -$5.28 M(-9.1%) |
| Dec 2011 | - | -$1.28 M(+18.1%) | -$5.81 M(-2.7%) |
| Sept 2011 | - | -$1.09 M(+15.6%) | -$5.97 M(+0.4%) |
| June 2011 | -$5.95 M(+22.7%) | -$939.40 K(-62.5%) | -$5.95 M(+2.2%) |
| Mar 2011 | - | -$2.50 M(+73.3%) | -$5.82 M(+2.0%) |
| Dec 2010 | - | -$1.45 M(+36.3%) | -$5.70 M(+10.1%) |
| Sept 2010 | - | -$1.06 M(+31.0%) | -$5.18 M(+6.9%) |
| June 2010 | -$4.85 M(+72.7%) | -$809.20 K(-66.1%) | -$4.85 M(+4.0%) |
| Mar 2010 | - | -$2.39 M(+159.3%) | -$4.66 M(+52.3%) |
| Dec 2009 | - | -$921.60 K(+26.7%) | -$3.06 M(+10.1%) |
| Sept 2009 | - | -$727.30 K(+16.9%) | -$2.78 M(-1.0%) |
| June 2009 | -$2.81 M(+1.0%) | -$622.10 K(-21.1%) | -$2.81 M(-11.6%) |
| Mar 2009 | - | -$788.60 K(+22.9%) | -$3.18 M(-0.5%) |
| Dec 2008 | - | -$641.50 K(-15.1%) | -$3.19 M(+8.1%) |
| Sept 2008 | - | -$755.20 K(-23.7%) | -$2.95 M(+6.3%) |
| June 2008 | -$2.78 M(-8.8%) | -$990.20 K(+23.3%) | -$2.78 M(+9.6%) |
| Mar 2008 | - | -$803.30 K(+99.0%) | -$2.54 M(-4.7%) |
| Dec 2007 | - | -$403.70 K(-30.6%) | -$2.66 M(-10.2%) |
| Sept 2007 | - | -$581.40 K(-22.2%) | -$2.96 M(-2.8%) |
| June 2007 | -$3.05 M(+23.6%) | -$746.90 K(-19.5%) | -$3.05 M(+32.5%) |
| Mar 2007 | - | -$927.70 K(+31.4%) | -$2.30 M(+67.6%) |
| Dec 2006 | - | -$705.80 K(+5.9%) | -$1.37 M(+105.9%) |
| Sept 2006 | - | -$666.20 K | -$666.20 K |
| June 2006 | -$2.46 M(+3633.3%) | - | - |
| June 2005 | -$66.00 K | - | - |
FAQ
- What is NanoViricides annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for NanoViricides?
- What is NanoViricides annual EBITDA year-on-year change?
- What is NanoViricides quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for NanoViricides?
- What is NanoViricides quarterly EBITDA year-on-year change?
- What is NanoViricides TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for NanoViricides?
- What is NanoViricides TTM EBITDA year-on-year change?
What is NanoViricides annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of NNVC is -$7.49 M
What is the all time high annual EBITDA for NanoViricides?
NanoViricides all-time high annual earnings before interest, taxes, depreciation & amortization is $1.93 M
What is NanoViricides annual EBITDA year-on-year change?
Over the past year, NNVC annual earnings before interest, taxes, depreciation & amortization has changed by +$354.80 K (+4.53%)
What is NanoViricides quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of NNVC is -$2.93 M
What is the all time high quarterly EBITDA for NanoViricides?
NanoViricides all-time high quarterly earnings before interest, taxes, depreciation & amortization is $4.10 M
What is NanoViricides quarterly EBITDA year-on-year change?
Over the past year, NNVC quarterly earnings before interest, taxes, depreciation & amortization has changed by -$1.19 M (-68.16%)
What is NanoViricides TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of NNVC is -$8.67 M
What is the all time high TTM EBITDA for NanoViricides?
NanoViricides all-time high TTM earnings before interest, taxes, depreciation & amortization is $1.68 M
What is NanoViricides TTM EBITDA year-on-year change?
Over the past year, NNVC TTM earnings before interest, taxes, depreciation & amortization has changed by -$476.60 K (-5.81%)